Patent · US Active

Recombinant adenoviruses and use thereof

US10781427B2 · kind B2 · utility

13Cited by
2References
29Claims
0Family size

Assignees

Inventors

Key dates

Filing dateOct 12, 2018
Grant dateSep 22, 2020
Priority date
Expiry dateOct 12, 2038

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.